Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years

Arthritis Care and Research

Volumn 69, Issue 2, 2017, Pages 257-262

  Aguiar, R ^a   Araujo C ^b   Martins Coelho, G ^c   Isenberg, D ^d  

^a Centro Hospitalar do Baixo Vouga EPE Avenida Artur Ravara   (Portugal)

^b HOSPITAL CURRY CABRAL   (Portugal)

^c University of Porto   (Portugal)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTERIAL INSUFFICIENCY; ARTERY THROMBOSIS; ARTICLE; BRITISH ISLES LUPUS ASSESSMENT GROUP SCORE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COMPLEMENT BLOOD LEVEL; DEATH; DISEASE ASSESSMENT; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 85010903651     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22921     Document Type: Article

References (25)

1. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195–205.
2. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958–67.
3. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:326–37.
4. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222–33.
5. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215–26.
6. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767–76.
7. Eisenberg RA, Khan S, Stansberry J, Tsai D, Kolasinski S, Rieder E, et al. An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus [abstract]. Arthritis Res Ther 2004;6 Suppl 3:92.
8. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482–7.
9. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458–66.
10. Witt M, Grunke M, Proft F, Aringer M, Burmester G, Chehab G, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE): results from a nationwide cohort in Germany (GRAID). Lupus 2013;22:1142–9.
11. Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol 2015;33:449–56.
12. Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24:17–23.
13. Condon MB, Damien A, Pepper R, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280–6.
14. Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 2012;51:476–81.
15. Dias SS, Rodriguez-Garcia V, Nguyen H, Pericleous C, Isenberg D. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford) 2015;54:1876–81.
16. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology (Oxford) 2001;40:205–11.
17. Edwards JC, Szcepanski K, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell targeted therapy with rituximab in rheumatoid arthritis. New Engl J Med 2004;35:2572–81.
18. Ramos L, Isenberg DA. Rituximab: the lupus journey. Curr Treat Opt Rheum 2015;1:30–41.
19. Días-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11:357–64.
20. Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Long-term follow-up in lupus nephritis patients treated with rituximab: clinical and histopathological response. Rheumatology (Oxford) 2013;52:847–55.
21. Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford) 2014;53:1570–7.
22. Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol 2016;26:80–6.
23. Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123–30.
24. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808.
25. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82.